CD22 and diffuse large B-cell lymphoma: Finally, we evaluated the internalization property on human lymphoma cell line of the anti-Human CD22 hLL-2 MAb, already used in phase I/II clinical trials for DLBCL treatment in humans, to obtain an element of comparison with the internalization property of the anti-CD22c MAbs.